Changes in Immunological Status in Patients With Metastatic Colorectal Cancer Treated With First-line Chemoimmunotherapy.
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Bevacizumab
/ therapeutic use
Colorectal Neoplasms
/ immunology
Female
Fluorouracil
/ therapeutic use
Humans
Immunotherapy
/ methods
Lymphocytes
/ drug effects
Male
Middle Aged
Monocytes
/ drug effects
Progression-Free Survival
Colorectal cancer
chemotherapy
immunological status
immunotherapy
αβ T cell therapy
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
23
05
2020
revised:
21
06
2020
accepted:
22
06
2020
entrez:
31
7
2020
pubmed:
31
7
2020
medline:
11
8
2020
Statut:
ppublish
Résumé
Chemoimmunotherapy is a promising treatment for various malignant diseases. In this study, we examined whether first-line chemoimmunotherapy using adoptive immune-cell therapy was effective for metastatic colorectal cancer (mCRC). The therapeutic efficacy and safety of the standard first-line chemoimmunotherapy with adoptive αβ T cell therapy and bevacizumab were assessed using thirty-two patients with mCRC in our hospital. Immunological status after this chemoimmunotherapy was also evaluated. The response and disease control rates were 68.8% and 87.5%, respectively. Further, median progression-free and overall survival were 14.2 and 35.3 months. Immunotherapy-associated toxicity was minimal. Significant decrease in the change of monocyte number (p=0.006) and increase in the change of rate of lymphocyte-to-monocyte ratio (p=0.039) were seen in the complete response group. First-line chemoimmunotherapy with adoptive αβ T cell therapy may be useful for mCRC.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
Chemoimmunotherapy is a promising treatment for various malignant diseases. In this study, we examined whether first-line chemoimmunotherapy using adoptive immune-cell therapy was effective for metastatic colorectal cancer (mCRC).
PATIENTS AND METHODS
METHODS
The therapeutic efficacy and safety of the standard first-line chemoimmunotherapy with adoptive αβ T cell therapy and bevacizumab were assessed using thirty-two patients with mCRC in our hospital. Immunological status after this chemoimmunotherapy was also evaluated.
RESULTS
RESULTS
The response and disease control rates were 68.8% and 87.5%, respectively. Further, median progression-free and overall survival were 14.2 and 35.3 months. Immunotherapy-associated toxicity was minimal. Significant decrease in the change of monocyte number (p=0.006) and increase in the change of rate of lymphocyte-to-monocyte ratio (p=0.039) were seen in the complete response group.
CONCLUSION
CONCLUSIONS
First-line chemoimmunotherapy with adoptive αβ T cell therapy may be useful for mCRC.
Identifiants
pubmed: 32727803
pii: 40/8/4763
doi: 10.21873/anticanres.14478
doi:
Substances chimiques
Bevacizumab
2S9ZZM9Q9V
Fluorouracil
U3P01618RT
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4763-4771Informations de copyright
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.